Spiethoff A, Wesch H, Wegener K, Hanisch E, Kaul A
Department of Biophysics and Medical Radiation Physics, German Cancer Research Center, Heidelberg.
Radiat Res. 1994 Jun;138(3):409-14.
To investigate whether there is a permanent translocation of Thorotrast in the body, the liver of male Lewis rats was removed 4 weeks after injection of Thorotrast (300 microliters) and replaced by a donor liver. In half of the animals the spleen was removed as well. Measuring the 232Th content in the donor liver at different times after implantation demonstrated a permanent transport of 232Th into the surrogate organ. After 231 days a 232Th depot of about 1.1 mg was found, representing about 3% of the total body burden. The additional removal of the spleen resulted in a significantly lower transport of 232Th into the implanted liver. Histological examinations of the donated livers revealed increasing local concentration of Thorotrast granules, leading to the development of conglomerates. A comparable translocation of Thorotrast was verified in two humans who required liver transplantation more than 40 years after Thorotrast injection.
为了研究钍造影剂在体内是否存在永久性移位，在给雄性Lewis大鼠注射钍造影剂（300微升）4周后，切除其肝脏，并用供体肝脏进行替换。在一半的动物中，脾脏也被切除。通过测量植入后不同时间供体肝脏中的钍-232含量，证实钍-232可永久性转运至替代器官。231天后，发现约1.1毫克的钍-232储存库，约占全身负荷的3%。额外切除脾脏导致钍-232向植入肝脏的转运显著降低。对捐赠肝脏的组织学检查显示，钍造影剂颗粒的局部浓度不断增加，导致团块形成。在两名在注射钍造影剂40多年后需要进行肝移植的患者中，也证实了钍造影剂存在类似的移位情况。
